For example, targeting and suppressing ZEB1 with the HDAC1-specific inhibitor mocetinostat or through the expression of miR-200 sensitizes resistant cancer cells to MEK inhibitors and reduces tumor growth in vivo [12]. Here, ZEB1 is linked to cancer.